Skip to content

Released Aug 6, 2019, after the close

10-Q filed Aug 6, 2019, 37 days after period end · 0001232524-19-000044

Q2 2019 · 10-Q
Revenue$534.13M+6.7% vs Q2 2018+5.1% vs Q1 2019
Net Income$261.90M+183.7% vs Q2 2018+207.4% vs Q1 2019
EPS Diluted$4.56+204.0% vs Q2 2018+210.2% vs Q1 2019
Gross Profit$495,747,000+7.4%
Operating Income$204,283,000+33.3%
Operating Cash Flowderived$148,847,000−22.5%
Free Cash Flowderived$134,884,000−28.2%
Margins · derived
Gross margin92.8%+0.6 pt vs Q2 2018
Operating margin38.2%+7.6 pt vs Q2 2018
Net margin49.0%+30.6 pt vs Q2 2018

What the release said

The release

Same quarter

MetricQ2 2019Q2 2018Q2 2017Q2 2016
Revenue$534.13M$500.48M$394.39M$381.16M
Net Income$261.90M$92.32M$105.60M$114.50M
EPS Diluted$4.56$1.50$1.72$1.85

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR